



October 14, 2016

## ImmunoGen, Inc. Announces Conference Call to Discuss its Financial Results for Quarter Ended September 30

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](#) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 28, 2016, to discuss ImmunoGen's financial results for the three-month period and fiscal year ended September 30, 2016. Management also will provide a brief update on the business.

To access the live call by phone, dial 913-312-0710; the conference ID is 4316729. The call also may be accessed through the Investors section of the Company's website, [www.immunogen.com](http://www.immunogen.com). Following the live webcast, a replay of the call will be available at the same location through November 11, 2016.

### About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is being advanced to a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease.

ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyła<sup>®</sup>, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at [www.immunogen.com](http://www.immunogen.com).

Kadcyła<sup>®</sup> is a registered trademark of Genentech, a member of the Roche Group.

View source version on [businesswire.com](http://businesswire.com): <http://www.businesswire.com/news/home/20161014005059/en/>

For Investors  
ImmunoGen, Inc.  
Sarah Kiely, 781-895-0600  
[sarah.kiely@immunogen.com](mailto:sarah.kiely@immunogen.com)

or  
For Media  
ImmunoGen, Inc.  
Amy Reilly, 781-895-0138  
[amy.reilly@immunogen.com](mailto:amy.reilly@immunogen.com)

or  
FTI Consulting Inc.  
Robert Stanislara, 212-850-5657  
[Robert.Stanislara@fticonsulting.com](mailto:Robert.Stanislara@fticonsulting.com)

Source: ImmunoGen, Inc.

News Provided by Acquire Media